Introduction
============

Acute respiratory tract infections are one of the leading causes of childhood morbidity and mortality worldwide, and it has been estimated that globally, respiratory infections are responsible for about 2 million deaths in children between 0 and 5 years of age ([@B17]; [@B53]). Approximately 80% of these respiratory infection cases are caused by viral pathogens such as influenza A and B, respiratory syncytial virus (RSV) A and B, parainfluenza virus types 1--3, adenovirus, rhinovirus, human metapneumovirus (hMPV), and others ([@B64]). The non-specific clinical presentation of respiratory infections poses a considerable challenge to the differential diagnosis of these pathogens. Early and accurate diagnosis of the causative pathogens in respiratory infections is essential to administer appropriate antiviral or antibacterial therapy, initiate effective infection control measures, and reduce the length of hospital stay ([@B8]; [@B20]; [@B2]). In the last decade, there has been a remarkable improvement in the diagnosis of respiratory pathogens with the availability of molecular and point-of-care (POC) testing. Although an increasing number of laboratories are adopting rapid molecular assays, conventional testing methods, such as culture and immunodiagnostics are still used. This review focuses on current laboratory methods for testing for respiratory pathogens, and discusses the advantages and disadvantages of each approach.

Non-Molecular Methods for Detection and Identification of Respiratory Pathogens
===============================================================================

Electron Microscopy
-------------------

Electron microscopy (EM) is one of the oldest direct examination methods that has been implemented for both clinical viral diagnosis and study of viral ultrastructure and pathogenesis in developed countries ([@B78]). Historically, EM has played an instrumental role in identifying novel viral strains in several outbreak situations, such as the coronavirus associated with the severe acute respiratory syndrome (SARS) outbreak ([@B30]; [@B56]). However, despite several advantages, the use of EM has been limited in respiratory viral diagnosis as it is expensive, laborious, time-consuming, and has a greater turnaround time (approximately 3--16 h including specimen preparation), and is often insensitive when compared to other diagnostic methods ([@B39]; [@B93]). Additionally, EM requires strict control of experimental conditions, a high concentration of viral particles (\> 10^5^ L^-1^), and considerable technical skill and expertise for accurate analysis.

Culture
-------

Detection of viruses by observing the cytopathic effect and hemadsorption in cell culture has been considered the "gold standard" for diagnosis of respiratory viral pathogens for decades. Viruses such as adenovirus, influenza A/B, RSV, and human parainfluenza viruses are the most common respiratory viruses that are isolated and detected by cell culture ([@B69]; [@B91]). The traditional tube culture method is advantageous for growing a wide variety of viruses, including novel or unknown viruses, but takes days and often weeks to provide results. Over the years, modified cell culture methods such as the centrifugation enhanced shell-vial method has reduced the turnaround time from 5 to 10 days to 24 h ([@B26]). Shell-vial culture using combination cell lines allows simultaneous detection of multiple respiratory viruses and, as compared to conventional culture, has similar sensitivity for parainfluenza 1-3 (87% vs. 83%) and influenza A/B (78% vs. 75%), and significantly higher sensitivity for RSV (73% vs. 42%) ([@B59]). Despite these advantages, many clinically relevant viruses are difficult to grow in culture (such as rhinovirus and coronavirus) and may produce variable results ([@B50]; [@B49]). Additionally, multiple freezing and thawing of the samples prior to testing can reduce the viral titer, thus effecting the growth in culture. Therefore, as compared to molecular tests, both traditional tube and shell-vial culture methods are laborious, exhibit higher false negative rates, and have longer turnaround times, making viral culture less clinically relevant ([@B60]; [@B37]; [@B48]).

Culture is also the gold standard for detection of atypical (bacterial) respiratory pathogens, which is followed by identification and antimicrobial susceptibility testing by various manual or automated methods ([@B86]). Bacterial culture can also often be insensitive, especially when specimen adequacy is not determined by Gram stain or if specimens were collected after antibiotic exposure ([@B5]; [@B92]; [@B47]). Bacterial culture is also labor intensive, requires substantial technical expertise, and has a typical turnaround time of 48 -- 96 h if antibiotic susceptibility testing is performed, and can therefore be considered inadequate for optimal patient care and guiding effective antimicrobial therapy ([@B86]).

Antigen Detection Assays
------------------------

### Rapid Immunoassays

Rapid immunoassays (RIAs) can deliver test results in less than 30 min and are usually performed in the POC setting, thus allowing the test results to be incorporated into the clinical decision-making algorithm ([@B88]). Among the four primary RIA formats (latex agglutination, horizontal flow devices, lateral flow devices, and optical immunoassays), the lateral-flow immunoassay (LFIA) is the most versatile and popular immunochromatographic method. RIAs are relatively inexpensive, easy to perform, and most of them have waived status in the United States according to the Clinical Laboratory Improvement Act (CLIA) guidelines, thereby making them invaluable in outpatient clinics, primary care, emergency, and low resource settings ([@B37]). Currently, commercially available RIAs are mostly limited to the detection of influenza A virus, influenza B virus, and RSV. Numerous studies have revealed that RIAs demonstrate overall poor sensitivity for influenza and RSV (44--95%); however, they have a higher median specificity (90 to 95%) as compared to cell culture ([@B90]; [@B60]; [@B37]).

In the pediatric population, commercially available immunoassays have demonstrated high sensitivity (93%) for detection of RSV, and a systematic review of published studies has further revealed that the sensitivity of RSV RIAs is relatively higher for children (81%) than adults (29%) ([@B84]; [@B22]). The higher sensitivity can be attributed to the fact that pediatric patients often shed higher titers of respiratory viruses and for a longer time as compared to adults ([@B29]; [@B54]). Despite the overall lower sensitivity, RIAs have been deemed a valuable diagnostic tool in the emergency department as they can significantly decrease the length of stay, additional ancillary testing, and antibiotic prescriptions for those children who do test positive for influenza ([@B1]; [@B12]).

### Direct Fluorescent Antibody Tests

Direct fluorescent antibody (DFA) testing of nasopharyngeal wash specimens is considered a rapid and reliable method for detecting respiratory viral infections. Commercial DFA kits have demonstrated high sensitivity and specificity for multiple respiratory viruses such as hMPV (95 and 100%), adenovirus (62 and 100%), RSV (94 and 96%), and parainfluenza viruses (88 and 99.7%), although the results can be subjective and require technical expertise for accurate interpretation ([@B58]; [@B68]; [@B76]; [@B4]; [@B87]). The high specificity (99--100%) of DFA indicates that the test can be used as a reliable detection method, especially during the initial days of the illness, as was shown by [@B83] for RSV in children.

Serological Tests
-----------------

Pathogen-specific antibodies typically appear about 2 weeks after the initial infection and can be detected by serological tests. Serological tests can successfully identify antibodies to most respiratory pathogens such as RSV, adenovirus, influenza A and B, parainfluenza 1-3 virus, etc., and can detect mixed infections from hospitalized children suffering from acute respiratory infections, with the exception of infants for whom an antibody response is usually undetected ([@B45]; [@B23]). However, it has been reported that serological assays are significantly less sensitive for the detection of parainfluenza virus and adenovirus when compared to molecular methods, such as RT-PCR ([@B57]). [@B57] found that RT-PCR detected 40% more specimens from pediatric patients that were positive for at least one respiratory virus than were detected by fluorescent antibody assay (FA). FA testing, in addition to RT-PCR, is useful for epidemiological studies as it increases the probability of identifying acute viral infections and has been used for accurate assessment of respiratory viruses other than influenza in children ([@B80]; [@B34]; [@B94]).

For bacteria, serological testing is particularly challenging, especially for identifying atypical bacterial agents such as *Mycoplasma pneumoniae*. With varied sensitivity (14% -- 77%) and specificity (49% -- 97%) as compared to PCR, serological testing has limited usefulness clinically ([@B10]; [@B89]). The clinical utility of serologic tests is further limited because they require both acute and convalescent sera to monitor seroconversion or to identify a four-fold increase in antibody titer ([@B63]). Additionally, serological tests are not relevant for identifying frequently recurring viral infections as the serum IgM levels are lower due to repeated exposure to vaccines or circulating viruses. For optimal virus specific IgM testing, an acute-phase serum specimen should be obtained early in the course of illness ([@B28]).

Nucleic Acid Amplification Tests for Detection and Identification of Respiratory Pathogens
==========================================================================================

A wide variety of newer, nucleic acid amplification tests (NAATs) for the detection of respiratory pathogens are commercially available. These tests are listed in **Table [1](#T1){ref-type="table"}** and described below according to complexity and pathogen coverage. The accuracy of respiratory virus detection by molecular tests is not only dependent on their specific assay chemistry, but is also critically affected by the type, quantity, and quality of specimens collected ([@B28]). Several types of specimens can be used for detection of respiratory viruses, including: bronchoalveolar lavage (BAL), throat swab, nasopharyngeal (NP) washes, NP aspirates, lung aspirates, and NP swabs, although the appropriate specimen type depends on the specific patient population. For example, in pediatric patients, obtaining nasal washes and nasal aspirates is more technically challenging when compared to NP swabs, especially in severely ill children and in poor resource settings ([@B46]). It has been observed that for optimal test results, specimens should be collected within 3--5 days after onset of symptoms to ensure that the sample has a high concentration of virus particles, viral antigen or viral nucleic acids, should be transported to the testing laboratory in refrigerated condition (2--8°C) in appropriate transport media, and testing should be performed within 48 h ([@B44]).

###### 

Commercially available nucleic acid amplification assays for respiratory pathogens^a^.

  Test                                                      Manufacturer                  Technology                                             Targets                                 Sample type^b^    Turnaround time   Complexity classification
  --------------------------------------------------------- ----------------------------- ------------------------------------------------------ --------------------------------------- ----------------- ----------------- ---------------------------
  NxTAG^®^ respiratory pathogen panel                       Luminex Corporation           Real-time RT-PCR                                       Multiplex Panel (20 targets)            NPS               ∼4 h              High
  eSensor^®^ respiratory viral panel (RVP)                  GenMark Diagnostics           Multiplex microarray, competitive DNA hybridization    Multiplex Panel (14 targets)            NPS               ∼8 h              High
  Verigene^®^ RP flex                                       Luminex Corporation           RT-PCR & and microarray hybridization                  Multiplex Panel (16 targets)            NPS               ∼2 h              Moderate
  ePlex^®^ respiratory pathogen (RP) panel                  GenMark Diagnostics           RT-PCR                                                 Multiplex Panel (17 targets)            NPS               ∼2 h              Moderate
  FilmArray^®^ respiratory panel (RP)                       BioFire Diagnostics, Inc.,    Nested multiplex RT-PCR                                Multiplex Panel (20 targets)            NPS               ∼1 h              Moderate
  FilmArray^®^ respiratory panel 2 (RP2)                    BioFire Diagnostics, Inc.,    Nested multiplex RT-PCR                                Multiplex Panel (21 targets)            NPS               ∼45 min           Moderate
  FilmArray^®^ respiratory panel^®^ (RP) EZ                 BioFire Diagnostics, Inc.,    Nested multiplex RT-PCR                                Multiplex Panel (14 targets)            NPS               ∼1 h              Waived
  Lyra^®^ parainfluenza virus assay                         Quidel Corporation            Real-time RT-PCR                                       Parainfluenza virus types 1, 2, and 3   NS, NPS           ∼4 h              High
  Lyra^®^ RSV + hMPV assay                                  Quidel Corporation            Real-time RT-PCR                                       RSV, hMPV                               NS, NPS           ∼4 h              High
  Simplexa^TM^ flu A/B & RSV Kit                            Focus Diagnostics, Inc.,      Real-time RT-PCR                                       Flu A, Flu B, and RSV                   TS                \<4 h             High
  Panther fusion flu A/B/RSV                                Hologic, Inc.,                Real-time RT-PCR                                       Flu A, Flu B, and RSV                   NPS               ∼2.5 h            High
  Panther fusion paraflu assay                              Hologic, Inc.,                Real-time RT-PCR                                       Parainfluenza 1, 2, and 3               NPS               ∼2.5 h            High
  Panther fusion AdV/hMPV/RV assay                          Hologic, Inc.,                Real-time RT-PCR                                       Adenovirus, hMPV, and Rhinovirus        NPS               ∼2.5 h            High
  ARIES^®^ flu A/B & RSV assay                              Luminex Corporation           Real-time PCR                                          Flu A, Flu B, and RSV                   NPS               \<2 h             Moderate
  ARIES^®^ bordetella assay                                 Luminex Corporation           Real-time PCR                                          *B. pertussis, B. parapertussis*        NPS               \<2 h             Moderate
  Simplexa^TM^ flu A/B & RSV direct                         Focus Diagnostics, Inc.,      Real-time RT-PCR                                       Flu A, Flu B, and RSV                   NPS               \<2 h             Moderate
  Xpert^®^ flu/RSV XC                                       Cepheid                       Real-time RT-PCR                                       Flu A, Flu B, and RSV                   NPS, NA, and NW   \<1 h             Moderate
  Solana RSV + hMPV assay                                   Quidel Corporation            Isothermal RT-helicase-dependent amplification (HDA)   RSV, hMPV                               NS, NPS           ∼45 min           Moderate
  Illumigene^®^ mycoplasma direct DNA amplification assay   Meridian Bioscience, Inc.,    Loop-mediated isothermal DNA amplification (LAMP)      *Mycoplasma pneumoniae*                 NPS, TS           \<1 h             Moderate
  Illumigene pertussis DNA amplification assay              Meridian Bioscience, Inc.,    Loop-mediated isothermal DNA amplification (LAMP)      *Bordetella pertussis*                  NPS               \<1 h             Moderate
  Xpert^®^ xpress Flu/RSV                                   Cepheid                       Real-time RT-PCR                                       Flu A, Flu B, and RSV                   NPS, NA, and NW   ∼30 min           Waived
  Xpert^®^ xpress flu                                       Cepheid                       Real-time RT-PCR                                       Flu A, Flu B                            NPS, NA, and NW   ∼30 min           Waived
  cobas^®^ Liat influenza A/B & RSV assay                   Roche Molecular Diagnostics   Real-time RT-PCR                                       Flu A, Flu B, and RSV                   NPS               ∼20 min           Waived
  cobas^®^ Liat influenza A/B assay                         Roche Molecular Diagnostics   Real-time RT-PCR                                       Flu A, Flu B                            NPS               ∼20 min           Waived
  Alere i influenza A & B 2 test                            Abbott Laboratories           Isothermal nucleic acid amplification                  Flu A, Flu B                            NPS, NS           \<15 min          Waived
  Alere i RSV                                               Abbott Laboratories           Isothermal nucleic acid amplification                  RSV                                     NPS, NPS in VTM   \<15 min          Waived
                                                                                                                                                                                                                             

a

FDA 510(k) Premarket Notification (

FDA, 2018a

). Retrieved from

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm

;

b

NPS, nasopharyngeal swab; NS, nasal swab; NA, nasal aspirate; NW, nasal wash; TS, throat swab.

c

Waived for direct NS, NPS, and NA/NW specimens; Moderate for NS and NA/NW specimens eluted in transport media.

High Complexity Multiplex Panel Assays
--------------------------------------

Detection of respiratory pathogens by NAATs such as PCR, nucleic acid sequence-based amplification (NASBA), transcription mediated amplification (TMA), strand displacement amplification (SDA), loop-mediated isothermal amplification (LAMP), rolling circle amplification (RCA), etc., have gained immense popularity over the past decade. Large syndromic panels that can detect multiple pathogens simultaneously are beneficial for infection control, timely treatment decisions, and are substantially less expensive than detecting individual pathogens by monoplex real-time RT-PCR ([@B75]; [@B81]). These multiplex respiratory panels vary in terms of their complexity (high, moderate, or waived), throughput, pathogens detected, ability to subtype, instrumentation (batched or random access), workflow (stepwise or integrated sample-to-answer), ease of use, and time to result (several hours to minutes) ([@B21]; [@B55]; [@B65]). Studies have reported increased diagnostic yield (60% vs. 35%) and considerably higher sensitivity (80--100%) and specificity (82--100%) for these assays when compared to conventional diagnostic methods such as DFA, viral isolation, and immunoassays ([@B75]; [@B35]).

In comparison to other NAAT-based molecular methods, high-plex syndromic panels demonstrate comparable performance, although sensitivity and specificity might vary for individual targets ([@B79]). For example, greater than 99% specificity was observed for all targets except enterovirus/rhinovirus (94%), and the overall sensitivity ranged between (83--100%) when the NxTAG RPP and the Anyplex II RV16 assays were evaluated for detection of respiratory pathogens in hospitalized children ([@B16]). Syndromic panels can also detect bacterial infections and viral-bacterial coinfections, which is vital for developing effective treatment plans and prevention strategies ([@B13]; [@B16]). However, for novel pathogen strains, such as Flu A(H1N1pdm2009), panel tests often fail to identify the subtype and require confirmation by other tests ([@B18]).

Syndromic respiratory panels with high sample throughput can usually run 1--96 specimens and are mostly classified as high complexity assays according to CLIA guidelines, which indicates that running these panel requires considerable knowledge, training, and experience ([@B32]). It has been noted that these high throughput panels are ideal for batch testing, especially during outbreak situations and respiratory viral seasons when sample volumes are unusually high ([@B38]; [@B24]; [@B85]). Despite the advantages, implementation of high throughput panels can be challenging because of demanding sample preparation, processing, and result interpretation procedures, and the turnaround time varies from approximately 5--16 h ([@B9]).

Moderate Complexity Multiplex Integrated Systems
------------------------------------------------

Moderate complexity sample-to-answer molecular test systems have gained immense popularity over the last few years because of their ease of use, faster turnaround time, and efficient workflow. Currently, the United States. FDA-cleared sample-to-answer test systems include both low-plex, targeted assays and high-plex panels that can detect multiple pathogens and pathogen classes. These tests usually have low to moderate sample throughput (e.g., 1--12 samples/run), but have faster turnaround times when compared to batched, high throughput, multiplex panels ([@B72]). The high-plex, sample-to-answer panels can detect up to 12--20 pathogens based on the panel size. Most of these qualitative assays allow random access that ensures that tests can be performed on demand, and the reactions occur in closed cassettes or cartridges, thereby minimizing the risk of contamination ([@B73]; [@B71]).

Comparative studies evaluating the performance of these assays has reported more than 95% agreement between different commercial platforms, and greater than 85% sensitivity and 99% specificity in most cases ([@B7]). However, some high-plex sample-to-answer tests have demonstrated lower sensitivity for certain pathogens such as adenovirus (57%), influenza A(H1N1pdm09) (73%), and influenza B virus (77%) ([@B72]). Cross-reactivity between adenovirus subtypes has also been reported for some assays, but the differentiation of these groups is not deemed clinically important for routine diagnosis ([@B61]; [@B41]).

Despite a short turnaround time of 1--2 h, the clinical utility of these assays has been questioned since no statistically significant reduction in antibiotic prescription rates or mortality has been observed between patients who tested positive for a non-influenza virus and those who tested negative (48% vs. 49% respectively) ([@B42]). In some cases, a reduction in length of hospital stay (7 days vs. 9 days) and duration of isolation (75 h vs. 82 h) was observed ([@B77]; [@B2]). The primary concerns for the high-plex sample-to-answer assays are high cost per test, and the inability to order customized, targeted panels ([@B74]). Multiplex assays such as the Verigene RP *Flex* panel (Luminex) offer flexible testing and payment options by allowing users to order any combination of targets for an individual sample.

Low-Plex Integrated Test Systems
--------------------------------

Low-plex integrated respiratory test systems typically target 1--4 pathogens per assay. Comparative studies evaluating the performance of these assays has reported more than 90% concordance between different commercial platforms, and greater than 95% sensitivity and specificity in most cases ([@B27]; [@B82]; [@B66]). The total turnaround time per sample for these assays varies between ∼1--2 h, and the number of samples that can be tested in a standard 8-h work shift depends on the number of instruments available in the testing laboratory ([@B62]). Smaller panels targeting a few pathogens that can be run independently (random access) or simultaneously (random batch) could be a viable option for controlling laboratory costs. Therefore, when considering among various testing options, it is recommended that in addition to clinical performance, other assay characteristics such as ease of use, panel composition, total turnaround time, hands-on time, and cost be considered before implementing an assay in various clinical settings ([@B52]).

Waived Molecular Point-of-Care Tests
------------------------------------

Nucleic acid amplification based POC testing is relatively new in the realm of respiratory viral diagnosis and has generated contradicting opinions regarding their implementation and clinical utility. Molecular POC assays have extremely short turnaround times (\<30 min), minimal hands-on time (1--2 min), and can be easily operated by non-laboratory staff members, thereby making them suitable for near patient implementation and testing ([@B15]; [@B70]; [@B62]). Currently most of the United States. FDA-cleared commercial POC assays are limited to the detection of influenza A/B and RSV viruses, with the exception of the FilmArray^®^ RP EZ (BioFire) which detects 14 targets ([@B33]). Most of the studies evaluating the clinical performance of these assays have reported high sensitivity (87--100%) and specificity (\>98%) for detecting influenza A/B and RSV in pediatric and adult patients ([@B11]; [@B67]; [@B71]; [@B36]; [@B62]). However, these studies have also shown that the clinical performance varies and sensitivity is significantly low for influenza B (45.2--54.5%); therefore, the results should be interpreted with caution and additional confirmatory testing should be considered, depending on the clinical circumstances ([@B51]; [@B19]; [@B25]). Molecular POC tests can be costly and more prone to incorrect results and contamination, as the assays are usually performed by non-laboratory personnel and poor training, failure to follow manufacturer's instructions, and failure to perform adequate quality control might affect the accuracy of results ([@B6]). Currently, more evidence-based studies are required to understand the overall clinical utility of molecular POC testing, since no correlation has been observed between implementation of these tests and reduction of antibiotic usage or hospital length of stay ([@B3]; [@B14]).

Concluding Remarks
==================

Molecular testing has considerably improved the diagnosis of respiratory pathogens and is being considered as the new "gold standard". Although these tests have gained immense popularity, factors such as the patient population (adult, pediatric, and immunocompromised), the size of the laboratory, the purpose of testing (routine or urgent care), and cost/benefit ratio should be considered before implementing a particular assay. For example, during the 2012--2013 influenza outbreak, two nosocomial cases were identified at Memorial Sloan Kettering Cancer Center on January 1, 2013. Despite implementing appropriate infection control measures, five more cases were identified few days later on January 7, 2013. A delay in reporting the positive influenza result was observed as the laboratory was following the routine diagnostic algorithm, and this might have resulted in the subsequent cases of nosocomial infection. Following the 2012--2013 outbreak, the laboratory implemented the FilmArray^®^ RP for routine diagnosis and the Xpert^®^ Xpress Flu/RSV, a rapid molecular POC system, for seasonal use during epidemics and pandemics because the needs for routine testing and urgent care are completely different in these situations. Molecular tests are highly sensitive and specific and result in higher pathogen detection, and therefore physicians and attending clinicians should evaluate test results before initiating a particular course of treatment. Rapid molecular tests are best suited for routine diagnosis and outbreak situations; whereas, conventional methods, such as cell culture or EM could be considered for identifying novel strains of the pathogens.

With the introduction of new technologies, newer assays will be developed for respiratory and other pathogens. For example, using NP swab specimens from children, [@B40] demonstrated that untargeted next-generation sequencing-based metagenomics (mNGS) testing had excellent agreement (93%) with multiplex molecular panels and detected more viruses that were either not targeted by the panel or missed due to highly divergent genome sequences. They concluded that mNGS can be used for accurate and unbiased detection of expected or unexpected pathogens. Implementing mNGS downstream of rapid molecular panel testing has been proven useful for characterizing the nature of hospital-associated transmission events and directing the control strategies in pediatric populations during outbreak situations ([@B43]). However, diagnostic implementation of NGS is currently limited by incomplete understanding of analytical performance, high cost of the system and complexity of sequence data analysis. Future research will be necessary to focus on demonstrating the clinical utility of these new and upcoming assays in various patient populations and in resource limited settings.
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